Chronic Lymphocytic Leukemia

Treating An Elderly Woman with Chronic Lymphocytic Leukemia

The combination of ibrutinib and obinutuzumab has gained FDA approval for the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, based on data from the phase III iLLUMINATE trial.

Treatment for Relapsed Chronic Lymphocytic Leukemia

Jordan Gauthier, MD, MSc, discussed the results presented at the 2018 ASH Annual for this clinical trial and where the research is headed for patients with CLL. He also highlights another promising combination for this patient population that was presented at the meeting as well.

A triplet regimen consisting of chlorambucil and rituximab in combination with an individualized dose of lenalidomide can potentially be used as a frontline treatment for patients with advanced chronic lymphocytic leukemia who are older or unfit for standard treatment with fludarabine, cyclophosphamide, and rituximab.

Chronic Lymphocytic Leukemia

Jordan Gauthier, MD, MSc, discusses the rationale for combining ibrutinib with CD19-targeting chimeric antigen receptor T cells for the treatment of patients with chronic lymphocytic leukemia.